2. UroToday Home
  3. Video Lectures

ASCO GU 2025 Videos

Predicting BCG Therapy Response in High-Grade Non-Muscle Invasive Bladder Cancer - Weranja Ranasinghe
Real-World Treatment Patterns in Metastatic Hormone-Sensitive Prostate Cancer in the US - Umang Swami
Evolving Treatment Landscape for Non-Muscle Invasive Bladder Cancer Beyond BCG - Bogdana Schmidt
Improving PSA Doubling Time Calculation for High Risk Biochemical Recurrence - Alicia Morgans
LEGEND Trial: EG-70 in BCG-Refractory Non-Muscle Invasive Bladder Cancer - John Taylor
PARASEC Study Reveals Real-World Treatment Patterns After Darolutamide in ARAMIS Trial - Javier Puente
PSA Nadir Predicts Outcomes in Metastatic Hormone-Sensitive Prostate Cancer Patients - Hannah McManus
ENVISION Trial Evaluates UGN-102 for Recurrent Low-Grade NMIBC Bladder Cancer - Sandip Prasad
Cognitive Effects of Abiraterone vs Enzalutamide in Metastatic Castration-Resistant Prostate Cancer - Alicia Morgans
PREDICT Trial Investigates Biomarker-Guided Treatment for Advanced Prostate Cancer - Rana McKay
Genomic Landscape of Non-Muscle Invasive Bladder Cancer from UROMOL Consortium - Lars Dyrskjøt
Real-World Treatment Delays Between Lutetium-177 and Cabazitaxel in Advanced Prostate Cancer - Yeonjung Jo & Umang Swami
NEO-BLAST Trial: Evaluating Bladder Preservation After Neoadjuvant Therapy in Bladder Cancer - Marie-Pier St-Laurent
Detecting ctDNA in High-Risk Non-Muscle Invasive Bladder Cancer - Dan Isaac
Comparing EMBARK vs EAU High-Risk Biochemical Recurrence Criteria in Prostate Cancer - Ugo Falagario
Comparing Therapy Approaches for Advanced Upper Tract Urothelial Carcinoma - Joon Kyung Kim
TRITON3 Final Overall Survival Results for Rucaparib in BRCA-Mutated Prostate Cancer - Alan Bryce
LIBERTAS Clinical Trial Explores Treatment Optimization in mHSPC - Arun Azad
Investigating PARP Expression as Biomarker for Targeted Therapy in Prostate Cancer - Emmanuel Antonarakis
Understanding ctDNA Technology Applications for Cancer Detection and Characterization - Alexander Wyatt
Examining Post-Prostatectomy Metastasis Patterns in Hormone-Sensitive Prostate Cancer - Nicolas Sayegh
Global Disparities in Bladder Cancer Clinical Trial Availability Across Income Classifications - Koral Shah
Comparing ARPI Options Across Disease Volume and Metastatic Timing in mHSPC - Syed Arsalan Ahmed Naqvi & Irbaz Riaz
PERSIAN Trial Explores SBRT Benefits in Oligometastatic Hormone-Sensitive Prostate Cancer - Giulio Francolini
Talazoparib and Enzalutamide in Unselected mCRPC Patients - Neeraj Agarwal
Real-World Data on Treatment Patterns After PSMA-Targeted Therapy in mCRPC - Oliver Sartor
Targeting Lineage Plasticity in Prostate Cancer with EZH2 Inhibitor Mevrometostat - Michael Schweizer
Systematic Review of Real-World Outcomes of Radium-223 in mCRPC Treatment - Rana McKay
Circulating Tumor DNA as Prognostic Biomarker in Perioperative Management of Muscle Invasive Bladder Cancer - Nimira Alimohamed
Phase II ENZA-p Trial Explores Effect of Lutetium PSMA With Enzalutamide - Louise Emmett
Multimodal Artificial Intelligence Concordance Between Whole-Mount Specimens and Tissue Microarrays in Prostate Cancer Analysis - Adam Dicker
Immune Infiltration Gene Signatures Predict Response to Gemcitabine Docetaxel vs BCG in Bladder Cancer - Michael O'Donnell
Safety of Combining Radiotherapy with Antibody Drug Conjugates in Advanced Urothelial Carcinoma - Neil Desai
Circulating and Urinary Tumor DNA in Bladder Cancer Treatment and Surveillance - Alan Tan
Triplet Therapy in Kidney Cancer: Insights from COSMIC-313 and the Path Forward - Laurence Albiges
Mucoadhesive Gemcitabine Formulation for Upper Tract Urothelial Carcinoma - Marie-Pier St-Laurent
Cardiovascular Management in Advanced Prostate Cancer - Zeynep Irem Ozay
Cretostimogene Grenadenorepvec Expanded Access Program for BCG-Unresponsive Bladder Cancer - Sarah Psutka
TROPION-PanTumor01 Trial for Advanced Bladder Cancer - Funda Meric-Bernstam
Germline Testing for Risk Stratification in Low-Grade Bladder Cancer on Active Surveillance - Roberto Contieri
Bladder Cancer Risk Stratification Using Non-Coding RNA - Yair Lotan
Genomic Characterization of Young-Onset Bladder Cancer - Alina Basnet
EMBARK Trial Subanalysis for High-Risk Biochemical Recurrent Prostate Cancer - Stephen Freedland
Estrogen Patches Combined with AR Pathway Inhibitors Show Promise in Prostate Cancer Management - Nicholas James
Real-World Safety Profiles of First-Line Therapies for Advanced Urothelial Carcinoma - Amanda Nizam
Phase II Trial Results of Disitamab Vedotin and Toripalimab Combination for Muscle-Invasive Bladder Cancer - Xinan Sheng
Combination Lenvatinib-Tislelizumab for Fumarate Hydratase-Deficient Renal Cell Carcinoma - Wen Kong
Tumor Suppressor Gene Status Refines Prognosis and Treatment Selection in Metastatic Prostate Cancer - Martino Pedrani
ctDNA as a Prognostic Biomarker in Bladder Cancer Treatment Decisions - Nimira Alimohamed
Intravesical Antibody-Drug Conjugates for Bladder Cancer - Di Maria Jiang
IMPLEMENT Study Reveals Barriers to Treatment Intensification in Metastatic Prostate Cancer - Stacy Loeb
Radiation Therapy vs Surgery Outcomes in High-Risk Localized Prostate Cancer Patients - Soumyajit Roy
CALYPSO Trial: Savolitinib and Durvalumab in Advanced Papillary Renal Cancer - Francesca Jackson-Spence
Avelumab’s Survival Impact in Diabetic vs Non-Diabetic Bladder Cancer Patients - Shilpa Gupta
Adjuvant Nivolumab in High-Risk Muscle Invasive Bladder Cancer Analysis Shows Improved Outcomes for Patients: CheckMate 274 - Matthew Galsky
Underutilization of Genomic Testing in Metastatic Castration-Resistant Prostate Cancer - Pedro Barata
Advances in Non-Muscle Invasive Bladder Cancer Treatment Options - Bogdana Schmidt
RETAIN-2 Study Shows Promise for Bladder Cancer Preservation - Pooja Ghatalia
Global BCG Shortage Impacts Treatment for High-Risk Bladder Cancer Patients - Jens Bedke
Lutetium PSMA Therapy in mCRPC: Real-World Evidence from PRECISION Data Platform - Oliver Sartor
Registry Data Shows Risk Migration With Blue Light Cystoscopy - Alireza Ghoreifi & Siamak Daneshmand
Metastasis-Directed Therapy Improves Outcomes in Oligometastatic Prostate Cancer in WOLVERINE Study - Chad Tang
COTRIMS Study: Reducing Long-Term Toxicity in Metastatic Seminoma Treatment - Axel Heidenreich
177-Lutetium-PSMA vs Cabazitaxel: A Real-World mCRPC Study - Mike Wenzel
Gut Microbiome and Prostate Cancer: How Diet Impacts Disease Progression - Robert Thomas
The NIAGARA Trial Highlights the Role of Durvalumab in Bladder Cancer Treatment - Matthew Galsky
Micropapillary Histology in Bladder Cancer: A Retrospective Survival Analysis - Muhammad Alkazemi & Hikmat Al-Ahmadie
KEYMAKER-U03 Trial: Combinatorial Therapies for IO-Refractory Kidney Cancer - Kathryn Beckermann
ACCEL Trial Tests Actinium-225-PSMA-62 in Prostate Cancer - Ramy Saleh
Real-World Trends in Bone Health Agent Use for Metastatic Prostate Cancer - Umang Swami
REDUSE Trial: Comparing Denosumab Dosing Intervals in mCRPC - Arnoud Templeton
Patient-Level Data Confirms ARPI Value in mHSPC Treatment in Meta-Analysis - David Fisher
PORTOS Biomarker Guides Radiation Dose Escalation in Prostate Cancer Treatment - George Zhao & Alan Dal Pra
Darolutamide Monotherapy in Prostate Cancer: A Phase II Trial Overview - Xin Gao
Exploring Actinium-225 in PSMA-Targeted Therapy for Prostate Cancer - Michael Morris
Real-World Treatment Patterns in Advanced Prostate Cancer from PRECISION Data Platform - Oliver Sartor
ARASTEP Trial Tests Darolutamide and ADT in High-Risk Biochemically Recurrent Prostate Cancer - Alicia Morgans
Combining Genomic Classifier and Digital Pathology Artificial Intelligence in Prostate Cancer Risk Stratification - Daniel Spratt
Talazoparib Improves Survival in HRR-Mutated mCRPC Patients in TALAPRO-2 Trial - Karim Fizazi
Dual Immune Activation with EG-70 Targets Non-Muscle Invasive Bladder Cancer - Vikram Narayan
Enfortumab Vedotin and Pembrolizumab Demonstrate Durable Responses in Advanced Bladder Cancer - Thomas Powles
ARANOTE Trial Explores Darolutamide’s Role in High and Low-Volume Metastatic Prostate Cancer - Fred Saad
Real-World Data on Nadofarogene Firadenovec for BCG-Unresponsive Bladder Cancer - Mark Tyson & Jacob Moyer
Genomic Classifier Decipher® Guides Treatment Intensification in Post-Prostatectomy Patients - Phuoc Tran